Moderna stock (US60770K1034): Q1 2026 net income swings to $169.7M profit

Moderna Inc. reported Q1 2026 results with net income of $169.7 million on $179.1 million revenue, driven by a Genevant settlement, reversing prior-year loss. Shares active on Nasdaq.

Moderna Inc. posted strong Q1 2026 financial results, achieving net income of $169.7 million for the quarter ended March 31, 2026, compared to a net loss of $24.5 million in Q1 2025. The performance was propelled by $179.1 million in revenue, primarily from a Genevant settlement, with net income per share at $0.88 basic and $0.87 diluted, according to TradingView as of May 2026. This marks a significant turnaround for the biotech firm listed on Nasdaq.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Moderna Inc.
• Sector/industry: Biotechnology
• Headquarters/country: USA
• Core markets: Global, with strong US focus
• Key revenue drivers: mRNA vaccines and therapeutics
• Home exchange/listing venue: Nasdaq (MRNA)
• Trading currency: USD

Moderna: core business model

Moderna develops mRNA-based medicines and vaccines, pioneering messenger RNA technology for treatments targeting infectious diseases, oncology, and rare diseases. The company, headquartered in Cambridge, Massachusetts, leverages its platform to design and manufacture lipid nanoparticle-formulated mRNA drugs rapidly. This model proved pivotal during the COVID-19 pandemic with its Spikevax vaccine, establishing Moderna as a key player in biotech for US investors tracking innovation-driven growth.

Moderna's pipeline includes over 40 programs, with commercial focus on respiratory vaccines and expansion into personalized cancer therapies. Revenue stems from product sales, collaborations, and milestones, underscoring its relevance to the US healthcare sector amid ongoing demand for advanced therapeutics.

Main revenue and product drivers for Moderna

Primary revenue drivers include Spikevax sales, which generated billions in peak pandemic years, alongside emerging contributions from RSV vaccines and partnerships like with Merck on cancer candidates. The Q1 2026 revenue of $179.1 million highlights settlement gains, positioning Moderna for diversified income streams critical for Nasdaq-listed biotechs.

Key products in development feature mRNA-1345 for RSV and mRNA-1647 for CMV, with US regulatory milestones influencing future topline growth. These drivers align with US market priorities in preventive medicine and immunotherapy.

Industry trends and competitive position

The mRNA sector is expanding beyond COVID, with applications in oncology and rare diseases fueling competition from Pfizer-BioNTech and smaller innovators. Moderna's proprietary platform offers manufacturing speed advantages, vital for US investors eyeing biotech resilience post-pandemic.

Why Moderna matters for US investors

Listed on Nasdaq, Moderna provides US investors exposure to cutting-edge biotech with significant government contracts and a robust US trial network. Its role in national vaccine stockpiles and oncology advancements ties directly to American healthcare spending trends.

Conclusion

Moderna's Q1 2026 results demonstrate a profitable shift driven by settlements and core mRNA advancements, contrasting prior losses and signaling pipeline potential. Investors monitor upcoming conferences like Piper Sandler on December 2, 2025, for strategic updates. The company's US-centric operations and Nasdaq presence maintain its appeal amid biotech volatility.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.